In the last years, IGF-I treatment is being either tested in or proposed for a wide range of pathological circumstances, as Laron syndrome, chronic liver disease, intrauterine growth restriction, insulin resistance and diabetes, neurological disorders (Alzheimer’s disease and amyotrophic lateral sclerosis) and stroke, cystic fibrosis, wound healing, burns, etc. [36-48]. This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.